CD4 and non-small cell lung carcinoma: Accordingly, a decrease in peripheral blood Tregs after ipilimumab treatment in metastatic melanoma patients was associated to disease control and OS [36], while the baseline percentage of CD25+ FoxP3+ CD4 T cells in NSCLC patients treated with nivolumab was higher in non-responders [34].